• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 20
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 20
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    SARS-CoV-2 R&D: Is It Over?

    Sustainability: A New Threat or Opportunity for CDMOs?

    Advanced Therapy Manufacturing

    Advanced Therapy Packaging Trends

    CEO Spotlight: Darren Head
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    Piramal Pharma Solutions New API Plant in Canada Now Online

    MG America Appoints Claudio Radossi as President

    Catalent Invests $175M to Expand Mfg. Capabilities at Winchester, KY

    Sartorius Expands Manufacturing Site in Tunisia

    BioMoti Partners with Pharma Company to Develop Ovarian Cancer Treatment
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    Piramal Pharma Solutions New API Plant in Canada Now Online

    Selecting a CMO Partner for Sterile Injectable Manufacturing

    Catalent Invests $175M to Expand Mfg. Capabilities at Winchester, KY

    Grand Opening of Kodiak Sciences’ Bioconjugation Facility

    Vertex Expands Cell and Gene Therapy Footprint
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Selecting a CMO Partner for Sterile Injectable Manufacturing

    Royalty Pharma and Jefferies Invest $111M in ApiJect

    Cryoport Acquires Cell&Co BioServices for €6.2M

    Challenges of Developing Large Volume Drug/Device Combination Products for Parenteral SC Delivery

    Yourway Adds Capacity for Controlled Ambient Storage
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Selecting a CMO Partner for Sterile Injectable Manufacturing

    BioMoti Partners with Pharma Company to Develop Ovarian Cancer Treatment

    WCG Appoints Sam Srivastava CEO

    AffyXell Expands Manufacturing Partnership with GenScript ProBio

    ABL and Odimma Therapeutics Enter Development Agreement
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    FDA Inspection Trends Update

    Phase-Appropriate cGMP Considerations for Cell and Gene Therapy

    Sustainability: A New Threat or Opportunity for CDMOs?

    In Pursuit of Sustainability: How the Biopharma Industry Can Contribute

    Conducting Clinical Trials During the Pandemic: What Did We Learn?
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    IDT Biologika

    Quotient Sciences

    Vector Partners Limited

    CMC Pharmaceuticals

    Aphena Pharma Solutions
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    IDT Biologika

    Quotient Sciences

    Vector Partners Limited

    CMC Pharmaceuticals

    Aphena Pharma Solutions
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • White Papers
    • Podcasts
    • Infographics
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Features

    Are Biotech Companies Strong Investments?

    Biotech capital raised via IPO has increased dramatically over the past couple of years.

    Are Biotech Companies Strong Investments?
    Are Biotech Companies Strong Investments?
    Figure 1
    Are Biotech Companies Strong Investments?
    Figure 2
    Are Biotech Companies Strong Investments?
    Figure 4
    Related CONTENT
    • Mogene
    • MIDI Labs
    • Softweb Solutions
    • Reed-Lane
    • The Biopharma Frontier
    Jason Monteleone , CEO, Clinipace05.07.19
    The Q2 2019 initial public offerings (IPOs) market has heated up after a Q1 2019 slowdown partially driven by the longest government shutdown in U.S. history. Ernst and Young reported that 205 IPOs were executed in 2018 on the New York Stock Exchange (NYSE) and Nasdaq, raising almost $53 billion of capital. The biotechnology sector was represented well:

    EvaluatePharma tabulated 68 biotech IPOs in 2018, raising more than $7 billion of capital. The dramatic increase in biotech capital raised via IPO since 2016 can be seen in Figure 1.


    Figure 1.

    One interesting trend is the substantial increase in the average amount raised per biotech in 2012 ($51 million) compared to 2018 ($105 million). Additionally, the number of $100 million IPOs increased from two in 2012 to 31 in 2018—the previous high was 18 in 2014. While the government shutdown in Q1 2019 momentarily slowed the market, there were still 10 biotech offerings raising more than $1 billion of capital. Three biotech IPOs, led by Gossamer Bio, which raised $317.4 million, each raised more than $100 million. Perhaps most impressive is that the biotech capital raised in 2018 was more than 2016 and 2017 combined.

    The impact can be felt across the drug development landscape. Consider the following:
    • The number of companies with an active compound in their pipelines increased 53% from 2012 (2,705) to 2018 (4,134), per Pharmaprojects, January 2018;
    • Total drugs in development increased 46% from 2012 (10,452) to 2018 (15,267), per Pharmaprojects, January 2018;
    • Research and development spend outside of the top 30 pharmaceutical companies represented 37% of total pharmaceutical R&D spend in 2017, up from 28% in 2010, per PivotalFinancialConsulting.com, September 2018; and
    • Since 2012, 31 biotech companies have been acquired for potential valuations exceeding $1 billion each and $96 billion in aggregate, per Silicon Valley Bank’s Trends in Healthcare Investments and Exits 2019 and Clinipace market intelligence.
    Why all the investor interest in biotech?
    Investor interest is usually driven by a return on investment commensurate with the investment vehicle’s risk profile. Biotech companies, and drug development, in general are widely regarded as risky. Financial risk (most biotechs will need to raise additional funds), the length of time required to commercialize, and drug development risk (will the drug be safe and show efficacy) raise complications. Last year, a group at MIT calculated that success rates in drug development were 13.8% across all therapeutic areas. Or, said a different way, the failure rate was greater than 85%.

    Figure 2 shows the 10-year compounded annual return on various stock market composites. The S&P Biotech Exchange Traded Fund and the Nasdaq Biotech Index both have annual returns in the 18%-19%—not far off the Nasdaq 100 Technology Sector Index. The return premium for the increased risk is pretty healthy when compared to the Dow Jones Industrial Average (DJIA) and the S&P 500 Index, both at 12.3%. 


    Figure 2.

    In addition to examining biotech returns historically, it is worthwhile to see how the most recent batch of biotech IPOs has fared. The analysis in Figure 3 is based on data available at Nasdaq.com and IPOScoop.com and includes biotech IPOs from March 2018 through February 2019, with the original IPO price along with the April 19, 2019, closing price. A few caveats: This list excludes secondary offerings; there may be a few expected IPOs missing. Also, because these were provided by the sites, a few IPOs or microcap companies may not have been included.


    Figure 3.

    A few observations from the data:
    • 60 companies raised over $6.4 billion of capital with a current return of 0.1%—thus, an investor would currently have broken even with this stock portfolio;
    • 33 (55%) companies are currently below their IPO price; and
    • While the portfolio is stable, there is wild variability among the group: 11 companies have lost 50% of more from the original IPO price; 22 companies have lost between 1% and 50% from the original IPO price; 19 companies have gained up to 50%; 5 have gained between 50%-75%; and 3 have gained more than 100% of value.
    It appears that biotech investing should be pursued in accordance with most investment philosophies that recommend a balanced portfolio to manage risk and optimize returns. However, it is also clear that while a balanced portfolio can result in strong gains against the DIJA and the S&P, investments in the right companies can result in once-in-a-lifetime returns.

    The information in Figure 4 was taken from Silicon Valley Bank’s (SVB) “Trends in Healthcare Investments and Exits 2019” combined with research from Clinipace’s market intelligence team. The companies included have been dubbed “unicorns” by SVB because of their outsized returns—typically earning valuations exceeding $1 billion early in their evolution. The investments have been categorized as M&A (merger and acquisition) and IPO successes. The total valuation between the two groups is almost $93 billion. Some of these deals include potential milestone values to be achieved; if those  aren’t realized, then valuations could drop.


    Figure 4.

    Analyzing the data uncovers several key data points:
    • Companies with a focus on immuno-oncology and oncology dominate with almost $66 billion (71%) of the total returns;
    • Companies with an immunotherapy, gene, or cell therapy technology garnered almost $47 billion; and
    • The biotech community has become a source of R&D for large pharma, which completed a majority of the acquisitions.
    Are biotechs still attractive investments?
    Positive historical investment returns do not guarantee future successful returns. What makes the biotech sector such an appealing investment in 2019?

    Oncology
    The worldwide market for cancer drugs is estimated at $133 billion and expected to reach $200 billion by 2022, averaging 10–13% growth over the next five years, with the U.S. market reaching as much as $100 billion by 2022, averaging 12–15% growth, according to the IQVIA Institute for Human Data Science. According to some estimates, 30% of the revenue growth in the pharma industry will come from oncology, and probably nine of the top 20 products in 2024 will be oncology products.

    Immuno-oncology
    GlobalData estimates that the total immuno-oncology market will be worth approximately $14 billion in 2019 and $34 billion by 2024. Checkpoint inhibitors will drive the growth, growing from $10 billion in 2019 to $24 billion by 2024. Per IQVIA, the pipeline of immunotherapies is particularly active and includes almost 300 molecules with 60 separate mechanisms being evaluated in Phase I or Phase II clinical trials, which is a significant jump from the four mechanisms in Phase III trials or under regulatory review. These immunotherapy trials are being conducted across 34 different tumor types, indicating the broad-based application of this new approach to cancer treatment.

    Gene Therapy
    Per Allied Market Research, the global gene therapy market was valued at $584 million in 2016 and is estimated to reach $4.402 billion by 2023, registering a CAGR of 33.3% from 2017 to 2023. Manufacturers are also preparing for growth in this market. In April 2019, Catalent announced it would buy privately held Paragon Bioservices for $1.2 billion in cash, bolstering its capabilities to make gene therapy drugs for its biotech clients. Evercore ISI analyst Ross Muken said the M&A activity is likely to continue and expects contract manufacturers to expand their gene therapy capabilities due to the potential of these treatments to drive the next major leg of industry growth.

    FDA Approvals Increase
    The FDA’s current progressive approach to drug development is challenging the industry to develop novel approaches to clinical trial design and execution. While it remains to be seen if the new FDA commissioner will maintain this emphasis, recent trends have been positive. 2018 was a record year for new drug approvals (NDA) with 59. Perhaps even more important for the biotech sector is that 34 NDAs in 2018 came from companies outside Scrip’s list of the largest pharma/biotech companies based on revenue—a welcome statistic showing that increased investment is translating into more approved drugs.

    Failures
    Success and failure in drug development go hand in hand. Several of the unicorns previously mentioned have not panned out as expected.

    AbbVie had to write off about $4 billion for Stemcentrx following a Phase III study of Rovalpituzumab Tesirine (Rova-T) that had an overall shorter survival in the Rova-T arm. This is disappointing as Stemcentrx could have been worth as much as $10 billion had Rova-T been successful as a second-line therapy for advanced small-cell lung cancer.

    Late last year, Gilead took an $820 million impairment charge on its Kite Pharma acquisition because of the failure of KITE 585, which is one of four CAR-T assets in Kite’s pipeline that was undergoing a Phase I trial for multiple myeloma. Gilead chose to discontinue development due to sub-par efficacy data. Analysts have speculated that Gilead may have significant future impairment charges related to Kite.

    Johnson & Johnson abandoned development of AL-8176 (lumicitabine), an anti-RSV drug, wiping $900 million off the value of the assets it acquired from Alios Biopharma. This comes months after J&J took a $630 million hit tied to the suspension of clinical development of AL-8176.

    The aforementioned examples put the reward and risk of drug development on display. In some cases, biotechs that were great investments for some investors became poor investments for future acquirers—all within a matter of a few years.

    Will interest in biotechs continue?
    While nothing is certain, a strong case can be made that interest in biotechs will remain bullish.

    Market demand and growth trends
    Deloitte’s “2019 Global Life Sciences Outlook” indicates that worldwide prescription drug sales are expected to rise from $900 billion in 2019 to $1.2 trillion by 2024. From 2018 to 2024, the compounded annual growth rate for pharmaceutical drugs is expected to be 6.4%, or six times the 1.2% over 2011–2017.

    Strong demand to improve health care
    Global life expectancy trends are rising rapidly and expected to reach 74.4 years by 2022, up from 73.3 in 2017. Additionally, the demand for new novel therapies that address unmet needs and for improved access to better medicines will increase. Lastly, while it is estimated that $19 billion of prescription sales may be at risk due to patent expiries, with approximately half resulting in lost sales, these sales are expected to be made up with new therapeutics.

    Historical trend of favorable returns
    It is hard to argue with 18% compounded annual returns over the past decade. There are not many other sectors where investors can find that consistency and performance over that many years.

    Potential headwinds
    Factors that could result in depressed investor enthusiasm for biotechs would be:
    • A greater number of large post-acquisition or post-IPO biotech challenges could decrease overall valuations and spook investors;
    • While the 10-year U.S. Treasury rate has been less than 4% for the past 10 years, a material rate increase over time could impact the amount of money available for investment or change the risk/reward profiles of investors; and
    • A slowdown in the IPO market could reduce the fundraising abilities of biotechs.
    Overall impact
    Biotechnology companies are vital to both the overall economy and improved patient outcomes. According to the Biotechnology Innovation Organization, the U.S. bioscience industry directly employed 1.74 million in 2016, added 273,000 U.S. jobs since 2001, and makes a $2 trillion overall impact to the U.S economy. A quick tabulation of publicly traded biotech stocks (using Yahoo.com’s stock screener) shows over $680 billion of market cap value. Lastly, between 2014-2018, the FDA approved 94 drugs from companies outside the Scrip’s top 100.

    These numbers speak for themselves. The biotech sector has made a positive impact for patients, investors, and the economy. This strong performance historically, coupled with the expected rise in prescription drug sales and a continually increasing demand for health care innovations, provides a good reason for optimism for biotech’s future.

    *Note: Figure 3 is available for view in the online version of this article at ContractPharma.com


    Jason Monteleone joined Clinipace in October 2017, bringing extensive expertise in the midsized clinical research organization (CRO) sector. A recognized health care and life science leader with more than 20 years of experience, he accepted the role as CEO after several months of strategic consulting with the company. Prior to Clinipace, Monteleone founded Pivotal Financial Consulting LLC, was executive vice president and chief financial officer of Theorem Clinical Research, was chief financial officer of Omnicare Clinical Research and held executive finance positions at MDS Pharma Services and VIASYS Healthcare.
    Related Searches
    • ndas
    • abbvie
    • Biopharma
    • Phase I
    Suggested For You
    Mogene Mogene
    MIDI Labs MIDI Labs
    Softweb Solutions Softweb Solutions
    Reed-Lane Reed-Lane
    The Biopharma Frontier The Biopharma Frontier
    Swissfillon Completes Successful FDA Inspection Swissfillon Completes Successful FDA Inspection
    Catalent Expands Patient-Centric Dose Form Mfg. Capabilities Catalent Expands Patient-Centric Dose Form Mfg. Capabilities
    Kite Pharma Expands Mfg. Facility in MD Kite Pharma Expands Mfg. Facility in MD
    SomaLogic & Janssen Enter Agreement SomaLogic & Janssen Enter Agreement
    The Unfolding Pharma Product Mix The Unfolding Pharma Product Mix
    KASA to Support Generic Drug Review KASA to Support Generic Drug Review
    Catalent Expands OptiMelt Capabilities at Somerset CoE Catalent Expands OptiMelt Capabilities at Somerset CoE
    Are We Embracing FDA’s Messages? Are We Embracing FDA’s Messages?
    Early Development Trends Early Development Trends
    AI in Pharma: Transforming Data into Drugs AI in Pharma: Transforming Data into Drugs

    Related Content

    • Mogene

      ...
      Craig Morley, CEO 11.17.20

    • MIDI Labs

      MIDI Labs

      ...
      Jeanette Feery, Marketing Director 11.05.20

    • Softweb Solutions

      ...
      Micheal Jury, Marketing Manager 09.23.20


    • Serialization | Vials
      Reed-Lane

      Reed-Lane

      Reed-Lane is a privately owned contract packager located in northern New Jersey that has been serving the pharmaceutical market for over 60 years.
      Joe Luke, VP Sales & Marketing 10.25.19

    • The Biopharma Frontier

      Market to witness major growth in coming years
      Tim Wright, Editor 05.07.19

      Trending
      • Catalent Invests $175M To Expand Mfg. Capabilities At Winchester, KY | Contract Pharma
      • Sartorius Expands Manufacturing Site In Tunisia | Contract Pharma
      • Grand Opening Of Kodiak Sciences’ Bioconjugation Facility | Contract Pharma
      • Vertex Expands Cell And Gene Therapy Footprint | Contract Pharma
      • Emergex COVID-19 Vaccine Candidate Successfully Coated Onto Zosano Micro-Needle Patch | Contract Pharma
      Breaking News
      • Piramal Pharma Solutions New API Plant in Canada Now Online
      • MG America Appoints Claudio Radossi as President
      • Catalent Invests $175M to Expand Mfg. Capabilities at Winchester, KY
      • Sartorius Expands Manufacturing Site in Tunisia
      • BioMoti Partners with Pharma Company to Develop Ovarian Cancer Treatment
      View Breaking News >
      CURRENT ISSUE

      May 2022

      • Sustainability and the Biopharma Industry
      • Contract Manufacturing During COVID
      • Orphan Drugs in the United States
      • CEO Spotlight: Peter DeYoung
      • CEO Spotlight: Darren Head
      • Advanced Therapy Packaging Trends
      • Advanced Therapy Manufacturing
      • Sustainability: A New Threat or Opportunity for CDMOs?
      • SARS-CoV-2 R&D

      Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
      You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

      • About Us
      • Privacy Policy
      • Terms And Conditions
      • Contact Us

      follow us

      Subscribe
      Nutraceuticals World

      Latest Breaking News From Nutraceuticals World

      GOED Creates Infographic Highlighting Omega-3 Health Claims Approved in Europe
      Kyowa Hakko Appoints Dr. Colin Hill to Immuse Scientific Advisory Board
      Expert Consensus Statement: Diet is Best Primary Intervention to Achieve Diabetes Remission
      Coatings World

      Latest Breaking News From Coatings World

      Teknos Receives EcoVadis Gold Medal for Sustainability Performance
      AkzoNobel and Partners Team Up to Hack Carbon Reduction Challenges
      Five PPG Facilities in Ohio Recognized for Sustainability, Health, Safety Practices
      Medical Product Outsourcing

      Latest Breaking News From Medical Product Outsourcing

      Iterative Scopes Expands its Senior Leadership Team
      Viz.ai Raises $100 Million in Series D Funding
      FDA Clears Arterys' AI Mapping and Quantification Tools
      Contract Pharma

      Latest Breaking News From Contract Pharma

      Piramal Pharma Solutions New API Plant in Canada Now Online
      MG America Appoints Claudio Radossi as President
      Catalent Invests $175M to Expand Mfg. Capabilities at Winchester, KY
      Beauty Packaging

      Latest Breaking News From Beauty Packaging

      Authentic Beauty Concept Launches Second-Generation ‘Refill Bar’
      HASK Beauty Enters Exclusive Partnership with Amazon
      Garance Doré Launches Made in France Skincare Line
      Happi

      Latest Breaking News From Happi

      SPF Setting Spray, Lip Contour and Knotless Braids Are Hot Trends: Spate
      Nutrafol Launches Collagen Infusion
      ÄZ Craft Luxury Haircare Products Support All Hairstyles
      Ink World

      Latest Breaking News From Ink World

      Nazdar Celebrates 100 Years with a New Look
      hubergroup Chemicals Exhibits at Paint India for First Time
      Award for Sustainability: Evonik Receives Platinum Rating Again
      Label & Narrow Web

      Latest Breaking News From Label & Narrow Web

      Specialty announces move to new facility
      Mark Andy hosts dealer's open house in Warsaw
      Nazdar celebrates 100th anniversary with refreshed brand identity
      Nonwovens Industry

      Latest Breaking News From Nonwovens Industry

      3M to Expand in Nebraska
      Nicely Offers Nonwoven Slitters, Winders
      'Right' Hygiene Conference to be Held in June
      Orthopedic Design & Technology

      Latest Breaking News From Orthopedic Design & Technology

      FDA Clears Anika Therapeutics' X-Twist Knotless Fixation System
      Paragon 28 Rolls Out TenoTac 2.0 Hammertoe and Soft Tissue Repair
      Cionic Expands Scientific Advisory Board
      Printed Electronics Now

      Latest Breaking News From Printed Electronics Now

      Evonik Launches New Processing Aids for PV Wafer Cutting
      NREL Creates Highest Efficiency 1-Sun Solar Cell
      eMagin Wins People’s Choice Award at Display Week 2022

      Copyright © 2022 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

      AD BLOCKER DETECTED

      Our website is made possible by displaying online advertisements to our visitors.
      Please consider supporting us by disabling your ad blocker.


      FREE SUBSCRIPTION Already a subscriber? Login